6th Gynaecological Cancer Academy Workshop

The 6th Gynaecological Cancer Academy Workshop with joint sessions of ENGOT Translational Research Network and Phase 1-2 Network, was held in London in September 2015.

The opening session of the workshop challenged the topic 'How to classify patients with recurrent ovarian cancer'. For several decades, the recurrent ovarian cancer has been classified according to platinum-free interval. However, in the era of new target therapies, this classification may not be relevant and a molecular classification might be more appropriate.

In addition, the session ´Challenges in defining the criteria for response and progression in clinical trials´ challenged a critical discussion about usage of Response Evaluation Criteria In Solid Tumors (RECIST) criteria, Immune related Response Criteria (irRC), CA-125 and their variations in trials, and questioned their usage in the era of the era of targeted and immunologic therapies.

Interested to find out more?

Watch the free access* webcasts below from the 6th GCA Workshop.

*First time eAcademy users need to register for a free access account.

>>Start the process

Nicoletta Colombo, Italy Welcome and introduction: The changing landscape of clinical trials in the era of targeted and immunologic therapies: different patient selection, new endpoints, new responsible criteria       SESSION 1: HOW TO CLASSIFY PATIENTS WITH RECURRENT OVARIAN CANCER? Mansoor Raza Mirza, Denmark Debate: platinum-free interval is still a valid tool in guiding treatment decision - PRO     Jonathan A Ledermann, UK How to define platinum-resistance or sensitivity after several lines of treatment?     Sandro Pignata, Italy Debate: platinum-free interval is still a valid tool in guiding treatment decision - CON     Bradley Monk, USA How to measure the benefit of chemotherapy-free interval in a trial with maintenance targeted therapy? The importance combined endpoints     SESSION 2: JOINT MEETING TR GROUP, PHASE 1-2 GROUP AND GCA ATTENDEES   Iain McNeish, UK Potential actionable target pathways in the different types of ovarian cancer   Cristiana Sessa, Switzerland Available drugs targeting the known altered pathways in ovarian cancer